By 
Issued on behalf of Helus Pharma™
Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarter
USA News Group News Commentary
NEW YORK, July 17, 2026 /PRNewswire/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in contingent value rights tied to development and regulatory milestones, taking total potential consideration to as much as $9.25 per share, or about $3.8 billion. The offer is a 26% premium to AtaiBeckley's prior close of $5.36, and the target jumped more than 30% before the bell. Across the sector, stocks that spent years priced as science projects moved sharply higher on one simple repricing event: a large-cap acquirer just validated the market.
The Deal That Changed the Conversation
What Lilly bought is instructive. AtaiBeckley's lead asset, BPL-003, is an intranasal formulation of 5-MeO-DMT for treatment-resistant depression, and it holds FDA Breakthrough Therapy Designation. Phase 2b results linked it to statistically significant improvement beginning on Day 2, maintained through Day 57. The company is also advancing an MDMA-related program. Phase 3 topline data for BPL-003 is not expected until early 2029.
Read that timeline again, because it is the whole story. Lilly committed up to $3.8 billion for an asset whose pivotal data is nearly three years out. That was not a purchase of proven revenue. It was a purchase of position, by a company that had already pledged more than $10 billion in upfront payments across eight acquisitions this year while building a neuroscience franchise alongside its obesity and diabetes business. Lilly has history here: Prozac reshaped the treatment of depression and powered its last great expansion before the GLP-1 era.
Why Everything Else Moved Too
Lilly is not alone in the neighborhood. Johnson & Johnson has been building in psychedelic-adjacent mental health for years, and analysts framed the deal as Lilly moving onto that ground. When a strategic acquirer sets a price, every comparable asset gets marked against it, and that is the mechanical reason the sector rallied. But the deal did not arrive into a vacuum, and the regulatory groundwork underneath it matters more than the headline.
An April 2026 executive order directed the FDA to fast-track review of psychedelic therapies holding Breakthrough Therapy Designation, and the follow-through has been steady rather than symbolic. On July 13, HHS and the Department of Veterans Affairs signed a memorandum of understanding on cooperation in psychedelic drug trials, a meaningful signal given that the VA is the single largest potential customer for a PTSD or depression therapy in the country. On July 14, the FDA published final clinical guidance for developers and announced a public hearing, which Jefferies read as evidence the agency is trying to help sponsors rather than slow them. For a category that spent decades fighting the regulator, that is close to a reversal, and it explains why a large pharmaceutical company would underwrite a 2029 readout. The approval path is now legible enough to model.
What Helus Pharma Is Actually Carrying
Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company founded in 2019. It rebranded from Cybin Inc. and transferred its U.S. listing from the NYSE American to the Nasdaq Global Market in January 2026, a repositioning management framed as the shift from discovery-stage to commercial-ready.
The company develops what it calls novel serotonergic agonists, or NSAs: synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. That matters commercially, because these are proprietary, patented chemical entities rather than naturally occurring compounds. Helus reports more than 350 patent filings with over 100 granted, and the U.S. composition of matter patent covering its lead candidates is expected to run to at least 2041.
The lead program is HLP003, a deuterated psilocybin analog in Phase 3 for the adjunctive treatment of major depressive disorder, where it holds FDA Breakthrough Therapy Designation. The Phase 3 PARADIGM program comprises APPROACH, which has passed 88% enrollment and is tracking to a topline readout in Q4 2026; EMBRACE, a second pivotal study currently enrolling; and EXTEND, a rollover study collecting long-term safety and durability data. Helus has also partnered with TARA Mind on veteran access, which points to the program at the same VA channel Washington has been busy opening.
The second asset, HLP004, is a deuterated DMT candidate for generalized anxiety disorder. The study randomized 36 patients 2-to-1 active to placebo at 20 mg or 2 mg, given as two intramuscular doses three weeks apart. Patients entered with an average baseline HAM-A of 22 and remained symptomatic despite ongoing standard-of-care antidepressant therapy. The 20 mg dose produced an average improvement of more than 10 points on the HAM-A by week six on top of that existing therapy. At six months, the pooled population showed 67% responders and 39% in remission, adverse events were transient, and no drug-related serious adverse events were recorded. Helus intends to complete the design of the next HLP004 study by the end of Q3 2026.
Helus also has money in the bank against its readout. On June 25, 2026, it closed a US$50 million underwritten offering, selling 10,309,280 shares at US$4.85 through a syndicate led by Cantor and Barclays, with proceeds earmarked for HLP003, HLP004, the preclinical HLP005 program, and general corporate purposes. A clinical-stage company heading into a pivotal readout with fresh capital sits in a materially different position than one that has to raise into the result.
The Rest of the Late-Stage Cohort
The companies below are other publicly traded developers working the same therapeutic ground. They are named as sector context, not as endorsements or financial comparables to Helus Pharma, and several are developing competing therapies. Each sits at a different stage with a different molecule and a different risk profile. All of them moved on the Lilly news.
Compass Pathways plc (NASDAQ: CMPS) is the closest analog to the Helus lead program. Its COMP360 psilocybin candidate met its primary endpoints in both the COMP005 and COMP006 Phase 3 studies in treatment-resistant depression, and it has reported six-month durability data. Evercore ISI upgraded the stock to Outperform with a $21 target, and Stifel raised its target to $21 on a Buy rating. Compass rose about 7% on the news, helped by a second-order connection: AtaiBeckley was historically its largest shareholder, though that stake had fallen to 4.96% as of a February 2026 filing.
GH Research PLC (NASDAQ: GHRS) was the sharpest mover, jumping roughly 15%, and the reason is mechanistic. GH Research develops proprietary mebufotenin therapies, mebufotenin being 5-MeO-DMT, the same compound class underlying the BPL-003 asset Lilly just bought. Lead candidate GH001 is an inhalable formulation for treatment-resistant depression, with the intravenous GH002 behind it, and the company published its Phase 2b primary results in JAMA Psychiatry in March 2026. Shares traded near $29.75 against a 52-week range of $11.32 to $31.96, with a market capitalization around $2.04 billion. If the market wanted a direct read-across from the Lilly deal, GH Research was it.
Definium Therapeutics, Inc. (NASDAQ: DFTX), formerly Mind Medicine, carries the deepest late-stage pipeline in the group. Lead candidate DT120 ODT, an orally disintegrating tablet of lysergide tartrate previously known as MM120, is in five Phase 3 studies spanning generalized anxiety disorder, major depressive disorder, and post-traumatic stress disorder, and holds FDA Breakthrough Therapy Designation in GAD. The company reported positive Phase 3 Emerge results in major depressive disorder, priced an upsized $700 million offering on the back of it, and has flagged a Phase 3 PTSD study called Haven for fiscal 2027. The stock gained about 6% on the deal.
AtaiBeckley Inc. (NASDAQ: ATAI) is included because it is now the sector's benchmark, not despite it. Formed by the combination of atai Life Sciences and Beckley Psytech, its shares had gained roughly 31% year to date against a $1.97 billion market value as of Wednesday's close. As of this announcement, it no longer trades on its pipeline. It trades on a deal spread: the $6.75 cash consideration, CVRs worth up to $2.50 more, and the odds the transaction closes in Q3. That transition, from a science story to a takeout price, is exactly the event the rest of the sector is now measured against.
Validation Is Not the Same Thing as Approval
It is worth being clear-eyed about what today settled and what it did not. A large pharmaceutical company assigning a price to one pipeline does not make any other pipeline work. Helus Pharma has not reported its Phase 3 data, and HLP003 could miss. The HLP004 study enrolled 36 patients, which is a signal rather than proof, and its headline figure was a within-subject improvement from baseline, not a demonstration of superiority over placebo in a powered pivotal trial. The company generates no revenue and will need to fund a commercial launch it has not yet earned the right to run.
What changed is narrower and still real: the exit is now visible. For most of this sector's history, the bear case was not simply that the science might fail but that even successful science had nowhere to go, because no large acquirer would touch a Schedule I derivative and no regulator would move. This morning, the first half of that stopped being an argument. Lilly wrote the check, the FDA published the guidance, the VA signed the memorandum. That leaves the sector's late-stage names with a cleaner question than they had a year ago: not whether anyone will ever want this, but whether the data reads out. For Helus Pharma, the answer arrives in the fourth quarter.
CONTINUED... Follow Helus Pharma's progress toward its Q4 2026 APPROACH topline readout and get the full story and updates here.